AAAAAA

   
Results: 1-11 |
Results: 11
The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection
Authors: Garcia, F Plana, M Ortiz, GM Bonhoeffer, S Soriano, A Vidal, C Cruceta, A Arnedo, M Gil, C Pantaleo, G Pumarola, T Gallart, T Nixon, DF Miro, JM Gatell, JM
Citation: F. Garcia et al., The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection, AIDS, 15(9), 2001, pp. F29-F40
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
Authors: Martinez, E Blanco, JL Arnaiz, JA Perez-Cuevas, JB Mocroft, A Cruceta, A Marcos, MA Milinkovic, A Garcia-Viejo, MA Mallolas, J Carne, X Phillips, A Gatell, JM
Citation: E. Martinez et al., Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy, AIDS, 15(10), 2001, pp. 1261-1268
Predictors of progression in chronically infected naive patients with plasma viraemia below 5000 copies/ml and CD4 T lymphocytes greater than 500 x 10(6)/l
Authors: Garcia, F Plana, M Soriano, A Vidal, C Arnedo, M Gil, C Cruceta, A Pumarola, T Gallart, T Miro, JM Gatell, JM
Citation: F. Garcia et al., Predictors of progression in chronically infected naive patients with plasma viraemia below 5000 copies/ml and CD4 T lymphocytes greater than 500 x 10(6)/l, AIDS, 15(1), 2001, pp. 131-133
Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients
Authors: Mallolas, J Blanco, JL Sarasa, M Giner, V Martinez, E Garcia-Viejo, MA Arnaiz, JA Cruceta, A Soy, D Tuset, M Soriano, A Codina, C Pumarola, T Carne, X Gatell, JM
Citation: J. Mallolas et al., Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients, J ACQ IMM D, 25(3), 2000, pp. 229-235
Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish Earth-2 Study
Authors: Garcia, F Alonso, MM Romeu, J Knobel, H Arrizabalaga, J Ferrer, E Dalmau, D Ruiz, I Vidal, F Frances, A Segura, F Gomez-Sirvent, JL Cruceta, A Clotet, B Pumarola, T Gallart, T O'Brien, WA Miro, JM Gatell, JM
Citation: F. Garcia et al., Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish Earth-2 Study, J ACQ IMM D, 25(1), 2000, pp. 26-35
Residual low-level viral replication could explain discrepancies between viral load and CD4(+) cell response in human immunodeficiency virus-infectedpatients receiving antiretroviral therapy
Authors: Garcia, F Vidal, C Plana, M Cruceta, A Gallart, MT Pumarola, T Miro, JM Gatell, JM
Citation: F. Garcia et al., Residual low-level viral replication could explain discrepancies between viral load and CD4(+) cell response in human immunodeficiency virus-infectedpatients receiving antiretroviral therapy, CLIN INF D, 30(2), 2000, pp. 392-394
Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients
Authors: Podzamczer, D Miro, JM Ferrer, E Gatell, JM Ramon, JM Ribera, E Sirera, G Cruceta, A Knobel, H Domingo, P Polo, R Leyes, M Cosin, J Farinas, MC Arrizabalaga, J Martinez-Lacasa, J Gudiol, F
Citation: D. Podzamczer et al., Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients, EUR J CL M, 19(2), 2000, pp. 89-95
Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study
Authors: Garcia, F Knobel, H Sambeat, MA Arrizabalaga, J Aranda, M Romeu, J Dalmau, D Segura, F Gomez-Sirvent, JL Ferrer, E Cruceta, A Gallart, T Pumarola, T Miro, JM Gatell, JM
Citation: F. Garcia et al., Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study, AIDS, 14(16), 2000, pp. 2485-2494
Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection
Authors: Plana, M Garcia, F Gallart, T Tortajada, C Soriano, A Palou, E Maleno, MJ Barcelo, JJ Vidal, C Cruceta, A Miro, JM Gatell, JM
Citation: M. Plana et al., Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection, AIDS, 14(13), 2000, pp. 1921-1933
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study
Authors: Garcia, F Romeu, J Grau, I Sambeat, MA Dalmau, D Knobel, H Gomez-Sirvent, JL Arrizabalaga, J Cruceta, A Clotet, B Podzamczer, D Pumarola, T Gallart, T O'Brien, WA Miro, JM Gatell, JM
Citation: F. Garcia et al., A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study, AIDS, 13(17), 1999, pp. 2377-2388
Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
Authors: Garcia, F Plana, M Vidal, C Cruceta, A O'Brien, WA Pantaleo, G Pumarola, T Gallart, T Miro, JM Gatell, JM
Citation: F. Garcia et al., Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy, AIDS, 13(11), 1999, pp. F79-F86
Risultati: 1-11 |